Will the U.S. measles outbreak reach 1800 cases by April 30, 2026? Trade prediction market odds currently at 2% YES. Monitor latest CDC data.
This market has been archived. Historical content preserved below.
The United States has maintained exceptionally low measles incidence for decades, with widespread vaccination campaigns achieving herd immunity across most regions. The CDC publishes weekly measles surveillance data, making case counts transparently verifiable and market-resolvable. This market asks whether cumulative U.S. measles cases will reach 1800 by April 30, 2026—a threshold roughly 10-15 times higher than typical recent annual counts. The current 2% YES odds reflect strong trader confidence that such a spike is extraordinarily unlikely within the remaining timeframe. The prevailing prediction market price implies measles transmission is well-controlled, with minimal expectation of a sudden outbreak cascade in the next four days. Any meaningful climb toward 1800 cases would require a major catalyst: dramatic drops in vaccination uptake, discovery of new transmission clusters, or emergence of highly infectious variants. The steep NO-skew indicates the market is pricing in the robust effectiveness of the U.S. vaccination infrastructure and epidemiological surveillance system.
Measles epidemiology in the United States reflects decades of successful vaccination policy implementation. The measles, mumps, and rubella vaccine (MMR) rollout beginning in 1963 fundamentally transformed measles from an endemic childhood disease affecting millions annually into a rare imported or vaccine-preventable occurrence. By the 1990s, endemic measles transmission was nearly eliminated across North America. However, periodic outbreaks have resurged when vaccination rates dip below population immunity thresholds or when travelers import the virus from countries with lower immunization coverage. The 2019 measles outbreak, centered in Brooklyn and other communities with lower vaccination rates, reached approximately 1,300 confirmed cases—notable as the highest annual total in over two decades, yet still substantially below the 1,800-case threshold this market contemplates. What could push this market decisively toward YES? A sudden, dramatic decline in vaccination uptake would be the primary structural catalyst, alongside significant importation of measles from ongoing international outbreaks. The emergence of vaccine-resistant variants or widespread misinformation campaigns undermining vaccine confidence could theoretically create conditions for rapid uncontrolled spread. Travel-related importation from endemic regions represents a perpetual epidemiological risk, particularly if multiple independent transmission chains establish and amplify simultaneously. System failures in disease surveillance infrastructure could theoretically delay detection and response protocols. Conversely, multiple countervailing factors push the market firmly toward NO. Vaccination rates in most U.S. states remain above 90–95%, far exceeding established herd immunity thresholds. The CDC maintains robust surveillance networks capable of detecting and containing clusters through rapid response protocols. Modern healthcare infrastructure, public health messaging capabilities, and medical countermeasures are vastly more advanced than during historic outbreak eras. The 2% probability reflects trader consensus that overcoming these layered defenses within four days remains implausible; reaching 1,800 cumulative cases would represent a catastrophic, unprecedented failure of multiple redundant prevention systems. Historical precedent underscores this conviction. Even during the 2019 outbreak—the worst year in modern U.S. measles history—accumulating 1,300 cases required a full year of sustained transmission chains within specific geographic clusters. An acceleration to 1,800 total cases in four remaining days would demand exponential growth rates unprecedented in documented U.S. epidemiological records. The prediction market spread effectively prices zero material probability to such a deviation from epidemiological baselines. Traders appear anchored on vaccination efficacy, surveillance responsiveness, and the categorical implausibility of a measles wave large enough to double the worst recent annual count in less than a week.
This market resolves based on the CDC's official measles case count for the United States through April 30, 2026. Resolution requires verification of cumulative confirmed measles cases reaching or exceeding 1,800 by the end date; the market settles NO if the total remains below 1,800.
Polymarket Trade is an independent third-party interface to the Polymarket CLOB prediction market exchange on Polygon — not affiliated with Polymarket, Inc. Prediction markets aggregate trader expectations into real-time probability estimates. Every market question resolves YES or NO based on a specific event outcome; traders buy shares of the side they believe will resolve positively. Prices range 0¢ (certain no) to 100¢ (certain yes) and naturally reflect the crowd-implied probability of YES. Polymarket Trade is non-custodial — your funds never leave your wallet. Open the full interactive page linked above to place orders, see order book depth, and execute a trade.